Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program

Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market

30-Apr-2025 - Neogap Therapeutics, a Swedish biotechnology start-up developing personalised immunotherapy for cancer treatment, announced that it has been selected for the Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with ...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

"DISCO is uniquely positioned to transform cancer care"

18-Jan-2024 - DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...

Million-euro financial injection for cancer vaccines development

New European and US investors: Nouscom Raises €67.5 million in Oversubscribed Series C Financing Round

15-Nov-2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned ...

Bowel cancer: aspirin activates protective genes

Researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer.

03-Nov-2023 - Colorectal cancer (bowel cancer) is the third most common form of cancer worldwide, with around 1.9 million newly diagnosed cases and 900,000 deaths every year. Therefore, preventive substances represent an urgent clinical need. Aspirin/acetylsalicylic acid has proven to be one of the most ...

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui

Agreement represents strong strategic fit that leverages the company’s internal DNA damage response expertise and in-house ADC capabilities

02-Nov-2023 - Merck announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) ...

Obesity as a risk factor for colorectal cancer underestimated so far

Weight loss before diagnosis masks the association

29-Sep-2023 - Obesity is a known risk factor for colorectal cancer. Scientists at the German Cancer Research Center (DKFZ) have now demonstrated, using data from nearly half a million participants in the UK Biobank cohort, that this association has probably been significantly underestimated to date. The ...

AI Predictions for Colorectal Cancer: One Step Closer to Efficient Precision Oncology

11-Sep-2023 - Colorectal cancer (CRC) ranks second in leading causes of cancer-related deaths globally, according to the WHO. For the first time, researchers from Helmholtz Munich and the University of Technology Dresden (TU Dresden) show that artificial intelligence (AI)-based predictions can deliver ...

High-fat diets alter gut bacteria, boosting colorectal cancer risk in mice

Salk scientists pinpointed specific microbes and bile acids that become more prevalent in the guts of mice fed high-fat diets

30-Aug-2023 - The prevalence of colorectal cancer in people under the age of 50 has risen in recent decades. One suspected reason: the increasing rate of obesity and high-fat diets. Now, researchers at the Salk Institute and UC San Diego have discovered how high-fat diets can change gut bacteria and alter ...

Multi-cancer blood test shows real promise in NHS trial

13-Jun-2023 - An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those ...

Curcumin activates tumor suppressive signaling pathway

Researchers have identified a signaling pathway via which curcumin can suppress the metastasis of colorectal cancer cells

31-May-2023 - Colorectal cancer is one of the most common types of cancer worldwide. In over half of all cases, an important protective mechanism in cells is inactivated by mutations – the tumor suppressor gene p53. The product of this gene, a transcription factor, induces a microRNA molecule called miR-34, ...